Key Events This Week
1 Jun: Brooks Laboratories Ltd hits upper circuit amid robust buying pressure (Rs.68.55)
2 Jun: Sharp reversal as stock plunges to lower circuit amid heavy selling (Rs.65.86)
5 Jun: Week closes at Rs.66.77, up 1.55% for the week
Jun 19, 03:30 PM
BSE+NSE Vol: 12.74 k
1 Jun: Brooks Laboratories Ltd hits upper circuit amid robust buying pressure (Rs.68.55)
2 Jun: Sharp reversal as stock plunges to lower circuit amid heavy selling (Rs.65.86)
5 Jun: Week closes at Rs.66.77, up 1.55% for the week

Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
At Rs 69.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.98% on 09 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
At Rs 65.13, sellers were still queuing — but there were no buyers willing to take the other side. Brooks Laboratories Ltd locked at its lower circuit of 4.99% on 2 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock.
Read full news article
At Rs 68.55, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 4.99% on 1 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
Brooks Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 31 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Brooks Laboratories Ltd., a contract manufacturing pharmaceutical company, reported consolidated net profit of ₹1.52 crores for Q4 FY26, marking a sharp decline of 72.36% quarter-on-quarter and a troubling 204.11% year-on-year contraction. The Himachal Pradesh-based micro-cap company, with a market capitalisation of ₹194.00 crores, witnessed its stock surge 5.00% to ₹65.75 following the results announcement, though the broader context reveals a company grappling with severe operational headwinds and margin compression.
Read full news article
At Rs 65.29, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
At Rs 62.19, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Brooks Laboratories Ltd locked at its upper circuit of 5% on 27 May 2026, with buyers queuing and no sellers willing to part with shares.
Read full news articleWe hereby inform that the Company at its board meeting held today i.e 19th June 2026 has approved sale of 51220 equity shares held by the Company in Brooks Steriscience Limited to Steriscience Specialities Limited.
Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026.
Appointment of Chief Executive Officer.
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Brooks Laboratories Ltd has announced 1:16 rights issue, ex-date: 28 Jul 23